Gerber T, Schomerus H
Medical Clinic II, Diakoniekrankenhaus, Rotenburg, Germany.
Drugs. 2000 Dec;60(6):1353-70. doi: 10.2165/00003495-200060060-00008.
The pathogenesis of hepatic encephalopathy (HE) is unknown. Many theories have been proposed. Most established therapies are based on such theories but since no theory has have ever been proved, therapies have to be considered empiric. The spectrum of HE ranges from minimal cerebral functional deficits, which can only be found by sensitive psychometric tests, to coma with signs of decerebration. HE has arbitrarily been divided into stages. A number of precipitating factors are known and the first line of therapy should always be the elimination of these factors. The differential diagnosis includes all states of impaired consciousness and deficits in cerebral function in patients with chronic liver disease, and clinical and biochemical tests to differentiate are indicated. The therapeutic options for HE include: protein restriction only for a limited time in comatous patients; nonabsorbable antibiotics (aminoglycosides), which because of adverse effects are also limited to higher grades of HE: intestinal cleansing which is applicable in all degrees of HE; lactulose, branched chain aminoacids and ornithin aspartate which have been proven to be effective and can be applied long term in patients with lower grades of HE.
肝性脑病(HE)的发病机制尚不清楚。人们提出了许多理论。大多数已确立的疗法都基于这些理论,但由于从未有理论得到证实,因此这些疗法只能被视为经验性的。HE的范围从只能通过敏感的心理测量测试才能发现的轻微脑功能缺陷,到出现去大脑体征的昏迷。HE被随意地分为几个阶段。已知有许多诱发因素,治疗的首要措施始终应该是消除这些因素。鉴别诊断包括慢性肝病患者所有意识障碍和脑功能缺陷的状态,需要进行临床和生化检查以进行鉴别。HE的治疗选择包括:仅对昏迷患者在有限时间内限制蛋白质摄入;不可吸收的抗生素(氨基糖苷类),由于不良反应,也仅限于较高级别的HE;肠道清洁适用于所有程度的HE;乳果糖、支链氨基酸和鸟氨酸天冬氨酸已被证明有效,可长期应用于较低级别的HE患者。